$EWTX insider trading
Over the last 12 months, Edgewise Therapeutics insiders reported 1 buy totaling $199K and 12 sales totaling $19.5M across SEC Form 4 filings. 54% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $199K 1 event
- Sold · 12m
- $19.5M 12 events
- Events · 12m
- 13 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 54% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Donovan Joanne M.CMO · O | ▼ Sale | 9,441 | $43.71 | $413K | -52.3% | plan · 5 tranches |
| Aug 12, 2026 | Russell Alan JChief Scientific Officer · O·D | ▼ Sale | 5,901 | $43.73 | $258K | -15.8% | 3 tranches |
| Aug 12, 2026 | MOORE JOHN RGeneral Counsel · O | ▼ Sale | 5,016 | $43.82 | $220K | -22.1% | 4 tranches |
| Aug 12, 2026 | Derakhshan BehradChief Business Officer · O | ▼ Sale | 5,100 | $43.81 | $223K | -13.8% | 4 tranches |
| Aug 12, 2026 | KOCH KEVINPresident and CEO · O·D | ▼ Sale | 17,971 | $43.68 | $785K | -25.5% | 3 tranches |
| Jul 1, 2026 | Russell Alan JChief Scientific Officer · O·D | ▼ Sale | 200,000 | $39.41 | $7.9M | -89.1% | plan · 2 tranches |
| May 5, 2026 | Donovan Joanne M.CMO · O | ▼ Sale | 55,230 | $37.88 | $2.1M | -92.7% | plan · 2 tranches |
| Apr 1, 2026 | Donovan Joanne M.CMO · O | ▼ Sale | 28,662 | $32.31 | $926K | -74.9% | plan |
| Mar 31, 2026 | Donovan Joanne M.CMO · O | ▼ Sale | 21,338 | $32.12 | $685K | -69% | plan |
| Mar 27, 2026 | Donovan Joanne M.CMO · O | ▼ Sale | 16,358 | $30.98 | $507K | -63% | plan · 2 tranches |
| Jan 21, 2026 | Edris BadreddinD | ▼ Sale | 115,471 | $29.44 | $3.4M | -85.4% | plan · 5 tranches |
| Nov 12, 2025 | Russell Alan JChief Scientific Officer · O·D | ▼ Sale | 100,000 | $21.12 | $2.1M | -81% | — |
| Nov 11, 2025 | Fox Jonathan CD | ▲ Buy | 10,700 | $18.64 | $199K | +82.3% | — |
| Aug 26, 2025 | Russell Alan JChief Scientific Officer · O·D | ▼ Sale | 100,000 | $14.6 | $1.5M | -81% | — |
| Aug 12, 2025 | MOORE JOHN RGeneral Counsel · O | ▼ Sale | 2,098 | $13.39 | $28K | -17% | — |
| Aug 12, 2025 | Derakhshan BehradChief Business Officer · O | ▼ Sale | 2,491 | $13.39 | $33K | -9.5% | — |
| Aug 12, 2025 | Carruthers R MichaelChief Financial Officer · O | ▼ Sale | 1,428 | $13.39 | $19K | -1.6% | — |
| Aug 12, 2025 | Russell Alan JChief Scientific Officer · O·D | ▼ Sale | 1,907 | $13.39 | $26K | -7.5% | — |
| Aug 12, 2025 | KOCH KEVINPresident and CEO · O·D | ▼ Sale | 7,972 | $13.39 | $107K | -20.7% | — |
| Aug 12, 2025 | Donovan Joanne M.CMO · O | ▼ Sale | 2,862 | $13.39 | $38K | -10.1% | — |
Every $EWTX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Edgewise Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $EWTX feed.